Pharma News

Epilepsy medications increase people's risk of dementia by up to 60 per cent, new research suggests.

The US Food and Drug Administration (FDA) has announced that it will require additional time to review AbbVie and Neurocrine Biosciences, Inc’s elagolix for pain related to endometriosis.

AbbVie announced positive top-line results from the phase 3 SELECT-COMPARE clinical trial where after 12 weeks, 15 mg, once daily, upadacitinib (formerly ABT-494) met primary endpoints of ACR2...

WILMINGTON, Del.

Bagsværd, Denmark, 5 April 2018 ­- Novo Nordisk and EpiDestiny today announced that Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny's sickle cell disease (SCD) pro...

(Reuters) - Merck & Co’s (MRK.

Basel, April 9, 2018 - Novartis announced today that it has entered into an agreement and plan of merger with AveXis, Inc.

Biogen and partner Samsung Bioepis have agreed a deal that will allow their biosimilar version of AbbVie’s Humira to launch in Europe and the US.

Align Clinical CROBiopharmaceutical solutions organisation company Syneos Health has helped to establish Align Clinical CRO, a new industry standards group which aims to improve clinical trial collabo...

Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the Atlantic, four years after a pair of trial failures left its future in doubt.

Ingelheim, Germany and Nantes, France – 4 April, 2018 - Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today annou...

European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosi...